Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells

National Medical Journal of China

Volumn 91, Issue 32, 2011, Pages 2287-2292

  Jiang, Xue Jie ^a   Meng, Fan Yi ^a   Huang, Kai Kai ^a   Zhou, Hong Sheng ^a   Wang, Qiang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; LBH589; Leukemia, myelocytic, acute; Multidrug resistance associated protein 1; RAD001

Indexed keywords

DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; DRUG DERIVATIVE; HYDROXAMIC ACID; RAPAMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; FLOW CYTOMETRY; LEUKEMIA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL STRAIN HL 60; DRUG EFFECT; DRUG RESISTANCE; HUMAN;

APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; SIROLIMUS;

EID: 84870450492     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.32.015     Document Type: Article

References (15)

1. Baumann P, Hagemeier H, Mandl-Weber S, et al. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by RAD001. Anticancer Drugs, 2009, 20: 259-266.
2. Haritunians T, Mori A, O'Kelly J, et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia, 2007, 21: 333-339.
3. Crazzolara R, Cisterne A, Thien M, et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia Blood, 2009, 113: 3297-3306.
4. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105: 1768-1776.
5. Giles F, Fischer T, Cortes J, et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res, 2006, 12: 4628-4635.
6. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 2007, 85: 54-60.
7. Bohm A, Aichberger KJ, Mayerhofer M, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest, 2009, 39: 395-405.
8. Brachmann S, Fritsch C, Maira SM, et al. PI3K and mTOR inhibitors-a new generation of targeted anticancer agents. Cell Biology, 2009, 21: 1-5.
9. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111: 379-382.
10. Nishioka C, Ikezoe T, Yang J, et al. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia, 2008, 22: 2159-2168.
11. Zeng Z, Sarbassov dos D, Samudio U, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood, 2007, 109: 3509-3512.
12. Tazzari PL, Cappellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal ransduction network in human acute myelogenous leukemia blast. Leukemia, 2007, 21: 427-438.
13. McCubrey JA, Abrams SL, Ligresti G, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia, 2008, 22: 2080-2090.
14. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res, 2006, 12: 5165-5173.
15. Mancini M, Corradi V, Petta S, et al. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leykemia by raising the nuclear expression of c-ABL protein. Leuk Res, 2010, 34: 641-648.